Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 277 JPY 0.45% Market Closed
Market Cap: 1.2T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Eisai Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eisai Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Eisai Co Ltd
TSE:4523
Cash Paid for Dividends
-ÂĄ45.9B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash Paid for Dividends
-ÂĄ294.7B
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Daiichi Sankyo Co Ltd
TSE:4568
Cash Paid for Dividends
-ÂĄ95.8B
CAGR 3-Years
-22%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Cash Paid for Dividends
-ÂĄ66.8B
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash Paid for Dividends
-ÂĄ131.6B
CAGR 3-Years
-10%
CAGR 5-Years
-18%
CAGR 10-Years
-18%
Astellas Pharma Inc
TSE:4503
Cash Paid for Dividends
-ÂĄ125.5B
CAGR 3-Years
-17%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.2T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Intrinsic Value
7 097.77 JPY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Eisai Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-45.9B JPY

Based on the financial report for Sep 30, 2024, Eisai Co Ltd's Cash Paid for Dividends amounts to -45.9B JPY.

What is Eisai Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-1%

Over the last year, the Cash Paid for Dividends growth was 0%.

Back to Top